Berenson, James R <br/><br/>
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.  [electronic resource] 

 -  British journal of haematology  Oct 2006 
 - 174-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0007-1048 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2006.06280.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Arsenic Trioxide<br/>Arsenicals--administration & dosage<br/>Ascorbic Acid--administration & dosage<br/>Creatinine--blood<br/>Female<br/>Humans<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Multiple Myeloma--blood<br/>Oxides--administration & dosage<br/>Prospective Studies<br/>Recurrence<br/>Survival Analysis<br/>Treatment Outcome